Clinical Topics

Targeted Therapies Transform RCC Treatment Over Last Decade

by U.S. Medicine

June 19, 2018

WASHINGTON — In the last decade, the development of multiple molecular-targeted therapies has dramatically altered the treatment landscape for advanced renal cell carcinoma (RCC).

The rate of new drug approvals has outpaced the ability of most guidelines to keep up, with four therapies receiving approval or breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) in just the last year.

The following are approved targeted therapies for metastatic RCC with approval dates:

  • Sorafenib (2005)
  • Sunitinib (2006 for first-line use and in 2017 for adjuvant therapy)
  • Temsirolimus (2007)
  • Pazopanib (2009)
  • Everolimus (2009)
  • Bevacizumab + interferon alfa-2b (2010)
  • Axintinib (2012)
  • Nivolumab (2015)
  • Lenvatinib + everolimus (2016)
  • Cabozantinib (2017)
  • Nivolumab+ ipilimumab (2018), for patients with intermediate or poor risk

In addition, pembrolizumab plus lenvatinib and axitinib plus avelumab have received breakthrough therapy designation in the last year.

The targeted therapies fall into two main classes, vascular endothelial growth factor (VEGF) inhibitors or mammalian target of rapamycin (mTOR) inhibitors. The National Comprehensive Cancer Network (NCCN) recommends the VEGF inhibitors sunitinib, pazopanib, bevacizumab plus interferon alpha, and cabozantinib in the first-line setting for primarily clear cell renal cell carcinoma. Sorafenib, axitinib and lenvatinib plus everolimus are NCCN recommended second-line therapies.

Of the mTOR inhibitors, NCCN recommends temsirolimus as a first-line therapy for poor-prognosis patients. Everolimus is recommended as a second-line option.

The newest approved agent, nivolumab plus ipilimumab, combines two immune checkpoint inhibitors. Nivolumab targets the programmed death 1 (PD-1) checkpoint protein, while the monoclonal antibody ipilimumab inhibits the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) protein. The combination received FDA approval subsequent to publication of the 2018 NCCN guidelines.

In the phase 3 CheckMate-214 trial on which the FDA based its decision, the nivolumab/ipilimumab combination demonstrated a survival benefit as well as both higher response rates and more durable responses compared to sunitinib in patients with intermediate to poor risk. With a median follow-up of 25.2 months, patients on the combination drug had an 18-month overall survival of 75% and median overall survival was not reached, while those receiving sunitinib had a 60% 18-month overall survival and a median overall survival of 26 months. The combination reduced the risk of progression or death by 28% compared to the standard therapy.1

1Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, et. Al. CheckMate 214 Investigators. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi:10.1056/NEJMoa1712126. Epub 2018 Mar 21. PubMed PMID: 29562145.

Related Articles

Suicide risk under-appreciated among advanced lung cancer patients

Much of the focus on suicide at the VA is on recently discharged servicemembers who suffer from conditions such as depression or post-traumatic stress disorder (PTSD).

Veteran nephrologist labors to improve ESRD treatment at VA

When Terrence O’Neil, MD, retired as chief of nephrology at the James H. Quillen VAMC in Johnson City in December 2016, he left in his wake decades of work treating kidney disease—nearly 35 years in the Air Force and DoD, plus 11 more at VA.

U.S. Medicine Recommends

More From oncology


Suicide risk under-appreciated among advanced lung cancer patients

Much of the focus on suicide at the VA is on recently discharged servicemembers who suffer from conditions such as depression or post-traumatic stress disorder (PTSD).


New Agents Extend Options for Increased Survival in Metastatic Prostate Cancer

Accounting for nearly a third of all cancer diagnoses, prostate cancer is the most frequently diagnosed cancer in the VHA, where past research has suggested that the malignancy is caught earlier than in other healthcare systems.


Personalized Medicine Brightens Outlook for Most Common Kidney Cancer

In the past five years, 10 new system therapies have been approved for renal cell carcinoma (RCC), the most common type of kidney cancer.


Liver Cancer Continues to Rise, Even as VA Declares Victory Over HCV Infection

In March, then-VA Secretary David Shulkin, MD, announced at the annual Wharton Health Care Business Conference that the VA will have eliminated hepatitis C infections among all patients willing and able to be treated by next spring.


Undertreatment of Metastatic Pancreatic Cancer Treatment, Despite Guidelines

While many other cancers have seen dramatic improvement in outcomes in the past 20 years, pancreatic cancer remains one of the deadliest malignancies, regardless of stage at diagnosis, with an overall five-year survival rate of only 8%, according to the American Cancer Society.

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up